In contrast, an Asian cohort study from Singapore reported that macular atrophy increased from 12.5 to 18.8% in non-polypoidal choroidal vasculopathy (PCV) eyes and 6.7–15.6% in PCV eyes during the 1-year follow-up period under anti-VEGF therapy [24]. This evidence concerns the gene VEGFA and Polypoidal choroidal vasculopathy.